{"gene":"CRABP2","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":2019,"finding":"CRABP2 was co-immunoprecipitated with HuR in lung cancer cells, and overexpression of CRABP2 increased HuR protein levels, which in turn promoted integrin β1/FAK/ERK signaling to drive migration, invasion, and anoikis resistance.","method":"Co-immunoprecipitation, overexpression, knockdown with pathway inhibitors","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP and pathway rescue experiments, single lab, two orthogonal approaches","pmids":["30696915"],"is_preprint":false},{"year":2019,"finding":"In ER+ breast cancer cells, CRABP2 interacts with LATS1 and suppresses its ubiquitination-mediated degradation, thereby activating the Hippo pathway and inhibiting invasion/metastasis. Conversely, in ER− breast cancer cells, CRABP2 interaction with LATS1 promotes LATS1 ubiquitination, inactivating Hippo and promoting metastasis.","method":"Co-immunoprecipitation, Western blotting, shRNA knockdown, overexpression, tail-vein injection in vivo metastasis model","journal":"Journal of experimental & clinical cancer research : CR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus in vivo rescue, single lab, two orthogonal methods","pmids":["31419991"],"is_preprint":false},{"year":2019,"finding":"CRABP2 physically delivers all-trans retinoic acid (atRA) to retinoic acid receptors (RARs); NMR spectroscopy demonstrated that atRA binding suppresses widespread intermediate- and fast-time scale dynamics in CRABP2, leading to rigidification that stabilizes a homodimerization interface (helix α2, βC-βD loop, strands βI-βA, βH-βI loop) and reorganizes the nuclear localization signal and RAR-binding motif.","method":"Nuclear magnetic resonance (NMR) spectroscopy with functional validation of dynamic changes","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structural/dynamics study with detailed residue-level mapping of ligand-induced conformational changes, single lab but multiple NMR approaches","pmids":["31566355"],"is_preprint":false},{"year":2019,"finding":"Knockdown of CRABP2 or RAR in human endometrial stromal cells (HESCs) recapitulated the anti-deciduogenic effects of resveratrol, establishing that the CRABP2–RAR signaling axis is required for decidualization (induction of PRL, IGFBP1, and decidual senescence markers).","method":"siRNA knockdown, primary HESC culture, qPCR for decidual markers","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with specific cellular phenotype, single lab, two targets knocked down independently with convergent results","pmids":["30894514"],"is_preprint":false},{"year":2013,"finding":"CRABP2, RDH10, and RALDH2 form a linear PPARγ-regulated pathway required for ATRA production and signaling in human monocyte-derived dendritic cells; all three proteins were shown to be required for PPARγ-induced ATRA production.","method":"Functional knockdown, co-localization, PPARγ activation assays in human and murine DCs","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pathway epistasis via genetic knockdown of each component, single lab, multiple cell types tested","pmids":["23833249"],"is_preprint":false},{"year":2013,"finding":"CRABP2 promotes myoblast differentiation in C2C12 cells by regulating the cell cycle; its core promoter (−459 to −4 bp) contains MyoD and Sp1 binding sites, and EMSA plus site-directed mutagenesis confirmed that MyoD and Sp1 directly regulate CRABP2 transcription.","method":"Overexpression, site-directed mutagenesis, EMSA, promoter deletion analysis, C2C12 differentiation assay","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution (EMSA), mutagenesis, and functional differentiation assay in single study with multiple orthogonal methods","pmids":["23383201"],"is_preprint":false},{"year":2022,"finding":"CRABP2 expedites the binding of BAX and PARKIN (shown by Co-IP and GST pulldown), facilitating ubiquitination-mediated degradation of BAX, thereby attenuating mitochondrial apoptosis and promoting oxaliplatin resistance in gastric cancer cells.","method":"Co-immunoprecipitation, GST pulldown, ubiquitination assay, shRNA knockdown, CDX and PDX in vivo models","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — GST pulldown (Tier 1) plus Co-IP, ubiquitination assay, and in vivo validation; single lab, multiple orthogonal methods","pmids":["36195596"],"is_preprint":false},{"year":2022,"finding":"CRABP2 upregulates EZH2 expression in ovarian cancer cells (confirmed by Co-IP), and EZH2 then binds DNMT1 to methylate the TRIM16 promoter, silencing TRIM16 and promoting EMT and invasion.","method":"Co-immunoprecipitation, ChIP assay, bisulfite sequencing, siRNA knockdown, overexpression, in vivo xenograft","journal":"Environmental toxicology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus ChIP plus functional epistasis rescue, single lab, multiple orthogonal methods","pmids":["35442568"],"is_preprint":false},{"year":2024,"finding":"CRABP2 is a cyclin D3-specific binding protein; purified protein binding assays and structural analysis revealed that the CRABP2 cyclin D3-binding site overlaps with its nuclear localization sequence within the helix-loop-helix motif. Mutations blocking cyclin D3 binding also blocked retinoic acid binding and induced an alternative lid conformation occluding the binding pocket. AlphaFold modelling supported a ternary CDK4/6–cyclin D3–CRABP2 complex.","method":"In vitro binding assays with purified proteins, mutagenesis, X-ray crystallography (structural analysis), AlphaFold modelling","journal":"Structure (London, England : 1993)","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution with purified proteins, mutagenesis, and structural data in single study with multiple orthogonal methods","pmids":["39419021"],"is_preprint":false},{"year":2025,"finding":"Nuclear CRABP2 promotes colorectal cancer tumor growth by interacting with and downregulating the tumor suppressor RB1, while cytoplasmic CRABP2 interacts with AFG3L2 to promote PINK1/Parkin-mediated mitophagy that suppresses liver metastasis. A separate cytoplasmic AFG3L2–SLC25A39 axis was identified whereby CRABP2 increases mitochondrial glutathione stability to promote proliferation independently of nuclear RB1.","method":"Conditional knockout mouse model (Crabp2ΔIEC), subcutaneous xenograft, Co-IP (CRABP2–RB1, CRABP2–AFG3L2), in vitro and in vivo functional assays","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","confidence":"High","confidence_rationale":"Tier 2 / Moderate — genetic KO mouse model plus multiple Co-IPs and in vivo validation, single lab but multiple orthogonal methods establishing distinct nuclear vs cytoplasmic mechanisms","pmids":["40305785"],"is_preprint":false},{"year":2022,"finding":"CRABP2 expression in thyroid cancer cells promotes invasion via the integrin/focal adhesion kinase (FAK)/AKT signaling pathway, independent of canonical retinoic acid signaling; knockdown reduced retinoic acid sensitivity.","method":"shRNA knockdown, overexpression, invasion assays, pathway inhibition experiments","journal":"Endocrinology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — KD/OE with defined cellular phenotype and pathway inhibitor rescue, single lab","pmids":["36240291"],"is_preprint":false},{"year":2023,"finding":"HPV16 E6/E7 upregulates CRABP2 expression in cervical cancer cells; CRABP2 in turn activates integrin β1/FAK/ERK signaling via HuR to promote proliferation, migration, and invasion. Inhibition of ITGB1, FAK, or ERK reversed the CRABP2-driven phenotypes.","method":"siRNA knockdown, overexpression, Co-IP (CRABP2–HuR inferred from prior work), pathway inhibitors, HPV E6/E7 knockdown rescue","journal":"Biochemical genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis via pathway inhibitors plus HPV E6/E7 genetic manipulation, single lab","pmids":["38001389"],"is_preprint":false},{"year":2024,"finding":"CRABP2 promotes migration and invasion in prostate cancer cells by upregulating LAMB3 mRNA and protein, activating downstream PI3K/AKT and MAPK signaling pathways, as confirmed by RNA-seq and Western blotting.","method":"RNA-seq, overexpression, Western blotting, in vivo xenograft","journal":"Journal of biochemistry","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — RNA-seq plus Western blot pathway validation plus in vivo, single lab","pmids":["39038078"],"is_preprint":false},{"year":2024,"finding":"CRABP2 reduces ovarian cancer sensitivity to Olaparib by inhibiting Caspase-8 activity and decreasing ROS production; knockdown of CRABP2 activated Caspase-8 and increased ROS, enhancing Olaparib sensitivity in vitro and in xenograft models, and Caspase-8 knockdown reversed this effect.","method":"shRNA knockdown, flow cytometry (ROS, apoptosis), colony formation, Western blotting, 4D proteomics, xenograft","journal":"Chemico-biological interactions","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic epistasis (Caspase-8 rescue) plus in vivo validation, single lab, multiple methods","pmids":["38493911"],"is_preprint":false},{"year":2024,"finding":"NFIX directly regulates CRABP2 promoter activity, as demonstrated by in vitro luciferase reporter assays; CRABP2 was identified as a downstream transcriptional target of NFIX in mouse embryonic fibroblasts and confirmed in Marshall-Smith syndrome patient fibroblasts.","method":"Luciferase reporter assay, RNA sequencing, proteomics, qRT-PCR, Western blot in MEFs and patient fibroblasts","journal":"JBMR plus","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — luciferase reporter (Tier 1) but single lab, confirmed in patient cells as additional validation","pmids":["38827116"],"is_preprint":false},{"year":2021,"finding":"CRABP2 knockdown in breast cancer cells suppressed CRABP1 protein levels, demonstrating a CRABP2-dependent regulation of CRABP1 expression as a novel mechanism within the intracellular retinoic acid signaling system.","method":"shRNA knockdown of CRABP2, Western blotting for CRABP1 across multiple breast cancer cell lines","journal":"Biochemistry. Biokhimiia","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — single method (Western blot) but replicated across multiple cell lines of different origin, single lab","pmids":["33832420"],"is_preprint":false},{"year":2024,"finding":"TRβ negatively regulates RARβ expression by binding to its promoter, and RARβ positively regulates CRABP2 expression; demonstrated by EMSA and dual luciferase reporter assays in endometrial cancer cells.","method":"Electrophoretic mobility shift assay (EMSA), dual luciferase reporter assay, Western blotting, xenograft model","journal":"Frontiers in pharmacology","confidence":"Medium","confidence_rationale":"Tier 1 / Weak — EMSA and reporter assay are Tier 1 methods, but single lab and single study","pmids":["40371351"],"is_preprint":false},{"year":2025,"finding":"CRABP2 binds PLAAT4 protein and decreases its stability; PLAAT4 inhibition reversed the suppression of malignant phenotypes (migration, invasion, lipid droplet accumulation) caused by CRABP2 knockdown in NSCLC cells.","method":"Protein binding assay, shRNA knockdown, overexpression, xenograft, lipid droplet staining","journal":"Journal of Cancer","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, binding assay not fully described in abstract, rescue epistasis without full mechanistic detail","pmids":["40657374"],"is_preprint":false},{"year":2026,"finding":"MSC-secreted CRABP2 increases the proportion of regulatory T cells (Tregs), which suppress hepatic CXCL1/neutrophil axis inflammation in alcohol-induced liver injury; Treg depletion negated the protective effect of MSC-derived CRABP2.","method":"MSC infusion in mouse model, Foxp3-DTR/EGFP transgenic Treg-depletion, anti-CXCL1 treatment, flow cytometry","journal":"Cell communication and signaling : CCS","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic Treg depletion epistasis plus in vivo rescue experiment, single lab","pmids":["41629950"],"is_preprint":false},{"year":2024,"finding":"CRABP2 upregulates HIF1α protein levels and increases HIF1α nuclear localization in drug-resistant ovarian cancer cells; knockdown of HIF1α blocked the CRABP2-mediated chemotherapy resistance.","method":"shRNA knockdown, Western blotting, nuclear fractionation/immunofluorescence, cell viability assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — epistasis via HIF1α knockdown rescue, single lab, two orthogonal readouts (expression and localization)","pmids":["38195606"],"is_preprint":false},{"year":2025,"finding":"In colorectal cancer, CRABP2 promotes peritoneal metastasis through TGF-β/Smad-mediated EMT signaling and invadopodia formation; bioinformatics plus experimental validation showed CRABP2 drives cell protrusive structures and EMT marker changes.","method":"shRNA knockdown, overexpression, in vivo metastasis model, enrichment analyses with experimental verification of TGF-β/Smad pathway","journal":"Cellular signalling","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pathway placement primarily from enrichment analysis with limited direct mechanistic confirmation in abstract, single lab","pmids":["40505846"],"is_preprint":false}],"current_model":"CRABP2 is a cytoplasmic/nuclear lipid-binding protein that transports all-trans retinoic acid (atRA) to nuclear RAR receptors (a process accompanied by ligand-induced protein rigidification and homodimerization); it also functions as a cyclin D3-specific binding partner, regulates HuR-mediated integrin β1/FAK/ERK signaling to drive cancer cell invasion, modulates LATS1 stability to control Hippo pathway activity in an ER-status-dependent manner, facilitates BAX ubiquitination via PARKIN to attenuate mitochondrial apoptosis, and in its nuclear vs. cytoplasmic forms plays opposing roles in colorectal cancer—nuclear CRABP2 downregulates RB1 to promote tumor growth while cytoplasmic CRABP2 engages AFG3L2/PINK1/Parkin-mediated mitophagy to suppress metastasis."},"narrative":{"mechanistic_narrative":"CRABP2 is an intracellular all-trans retinoic acid (atRA) binding protein that physically delivers atRA to nuclear retinoic acid receptors (RARs), and ligand binding suppresses its conformational dynamics, rigidifying the protein to stabilize a homodimerization interface and reorganize the nuclear localization signal and RAR-binding motif [PMID:31566355]. This CRABP2-RAR axis is required for tissue-specific differentiation programs including endometrial stromal cell decidualization [PMID:30894514] and PPARγ-driven atRA production in dendritic cells, where CRABP2 acts within a linear RDH10/RALDH2 pathway [PMID:23833249]. Beyond retinoid transport, structural and reconstitution work establishes CRABP2 as a cyclin D3-specific binding partner whose cyclin D3-binding site overlaps its nuclear localization sequence within the helix-loop-helix motif, supporting a ternary CDK4/6-cyclin D3-CRABP2 complex; mutations that block cyclin D3 binding also abolish retinoic acid binding [PMID:39419021]. CRABP2 functions extensively as a protein-stability and signaling regulator in cancer: it binds HuR to drive integrin β1/FAK/ERK signaling and invasion [PMID:30696915, PMID:38001389], modulates LATS1 ubiquitination to tune Hippo pathway output in an estrogen-receptor-status-dependent manner [PMID:31419991], and promotes BAX ubiquitination via PARKIN to attenuate mitochondrial apoptosis and confer chemoresistance [PMID:36195596]. In colorectal cancer it exerts opposing compartment-specific roles, with nuclear CRABP2 downregulating the tumor suppressor RB1 to promote growth while cytoplasmic CRABP2 engages AFG3L2 to drive PINK1/Parkin mitophagy that suppresses metastasis [PMID:40305785]. CRABP2 transcription is directly controlled by MyoD and Sp1 during myoblast differentiation [PMID:23383201] and by NFIX [PMID:38827116].","teleology":[{"year":2013,"claim":"Establishing how CRABP2 is itself controlled and what cellular program it serves, transcriptional and pathway-level studies placed it within differentiation circuits.","evidence":"EMSA, promoter deletion and mutagenesis in C2C12 myoblasts; functional knockdown and co-localization in human/murine dendritic cells","pmids":["23383201","23833249"],"confidence":"High","gaps":["Whether the same transcriptional inputs operate in non-muscle tissues was not addressed","The DC pathway epistasis did not resolve direct biochemical handoffs between RDH10, RALDH2 and CRABP2"]},{"year":2019,"claim":"Residue-level structural dynamics answered how atRA binding converts CRABP2 into a delivery-competent state, linking ligand occupancy to dimerization and nuclear targeting.","evidence":"NMR spectroscopy with functional validation of ligand-induced rigidification","pmids":["31566355"],"confidence":"High","gaps":["The functional consequence of homodimerization for RAR delivery in cells was not measured","No structure of the CRABP2-RAR complex itself"]},{"year":2019,"claim":"Co-IP and in vivo studies revealed that CRABP2 acts beyond retinoid transport as a protein-interaction hub controlling HuR-driven invasion signaling and context-dependent LATS1/Hippo regulation, and that the CRABP2-RAR axis is required for decidualization.","evidence":"Reciprocal Co-IP plus pathway inhibitor rescue in lung cancer; Co-IP with tail-vein metastasis model in ER+/ER- breast cancer; siRNA in primary endometrial stromal cells","pmids":["30696915","31419991","30894514"],"confidence":"Medium","gaps":["Mechanism by which ER status reverses the LATS1 ubiquitination outcome is unresolved","How CRABP2 stabilizes HuR protein is not defined"]},{"year":2022,"claim":"Biochemical and in vivo work defined CRABP2 as a ubiquitination scaffold that promotes BAX degradation via PARKIN, mechanistically connecting it to apoptosis evasion and drug resistance.","evidence":"GST pulldown, Co-IP, ubiquitination assay, shRNA, CDX/PDX models in gastric cancer","pmids":["36195596"],"confidence":"High","gaps":["Whether CRABP2 directly bridges BAX-PARKIN or acts allosterically is unclear","No structural model of the CRABP2-BAX-PARKIN assembly"]},{"year":2022,"claim":"Additional cancer studies extended CRABP2's regulatory reach to epigenetic silencing (EZH2/DNMT1/TRIM16) and FAK/AKT-driven invasion independent of canonical retinoic acid signaling.","evidence":"Co-IP, ChIP, bisulfite sequencing in ovarian cancer; shRNA and pathway inhibition in thyroid cancer","pmids":["35442568","36240291"],"confidence":"Medium","gaps":["Direct biochemical link between cytoplasmic CRABP2 and nuclear EZH2 upregulation not established","FAK/AKT activation mechanism downstream of CRABP2 not biochemically defined"]},{"year":2024,"claim":"Structural reconstitution resolved a non-retinoid function of CRABP2 as a cyclin D3 partner, showing the binding sites for cyclin D3 and retinoic acid are mutually exclusive and embedded in the NLS.","evidence":"Purified protein binding assays, mutagenesis, X-ray crystallography, AlphaFold modelling of a CDK4/6-cyclin D3-CRABP2 complex","pmids":["39419021"],"confidence":"High","gaps":["Cellular consequence of the ternary CDK4/6-cyclin D3-CRABP2 complex on cell cycle not demonstrated","Whether retinoic acid competes off cyclin D3 in cells is untested"]},{"year":2024,"claim":"A cluster of studies mapped CRABP2 into chemoresistance and signaling outputs (HIF1α, Caspase-8/ROS, LAMB3-PI3K/AKT) and into a transcriptional network with NFIX and TRβ/RARβ.","evidence":"shRNA epistasis and xenografts in ovarian cancer; RNA-seq in prostate cancer; luciferase reporters in MEFs/patient fibroblasts and endometrial cancer cells","pmids":["38195606","38493911","39038078","38827116","40371351"],"confidence":"Medium","gaps":["Whether these downstream effectors are direct or indirect targets of CRABP2 is largely unresolved","Tissue specificity of the transcriptional regulators is not generalized"]},{"year":2025,"claim":"A conditional knockout mouse defined opposing subcellular roles of CRABP2 in colorectal cancer, with nuclear CRABP2 suppressing RB1 to drive growth and cytoplasmic CRABP2 engaging AFG3L2-mediated mitophagy and mitochondrial glutathione control.","evidence":"Crabp2 intestinal-epithelial conditional knockout, xenografts, multiple Co-IPs (RB1, AFG3L2)","pmids":["40305785"],"confidence":"High","gaps":["Signal that partitions CRABP2 between nucleus and cytoplasm is not identified","How CRABP2 downregulates RB1 mechanistically is undefined"]},{"year":2026,"claim":"An immunological role emerged for secreted CRABP2 in dampening hepatic inflammation via regulatory T-cell expansion.","evidence":"MSC infusion with Foxp3-DTR Treg depletion and anti-CXCL1 in a mouse alcohol liver injury model","pmids":["41629950"],"confidence":"Medium","gaps":["Receptor or mechanism by which extracellular CRABP2 expands Tregs is unknown","Whether endogenous CRABP2 secretion is physiologically relevant is untested"]},{"year":null,"claim":"It remains unresolved how a single retinoic acid carrier is dynamically partitioned among its many reported roles—retinoid delivery, cyclin D3 binding, ubiquitination scaffolding, and mitophagy—and what governs its nuclear vs cytoplasmic vs secreted distribution.","evidence":"No single study integrates the competing binding modes or compartmental switches","pmids":[],"confidence":"Low","gaps":["No unifying model for partner selection","No determinant identified for subcellular targeting","Physiological versus oncogenic balance of functions unclear"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[2]},{"term_id":"GO:0140104","term_label":"molecular carrier activity","supporting_discovery_ids":[2]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,6,8]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[9]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[2,9]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,1,11]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[3,4,5]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[6,13]}],"complexes":["CDK4/6-cyclin D3-CRABP2"],"partners":["ELAVL1","LATS1","CCND3","BAX","PARK2","RB1","AFG3L2","PLAAT4"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P29373","full_name":"Cellular retinoic acid-binding protein 2","aliases":["Cellular retinoic acid-binding protein II","CRABP-II"],"length_aa":138,"mass_kda":15.7,"function":"Transports retinoic acid to the nucleus. Regulates the access of retinoic acid to the nuclear retinoic acid receptors","subcellular_location":"Cytoplasm; Endoplasmic reticulum; Nucleus","url":"https://www.uniprot.org/uniprotkb/P29373/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CRABP2","classification":"Not Classified","n_dependent_lines":3,"n_total_lines":1208,"dependency_fraction":0.0024834437086092716},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CRABP2","total_profiled":1310},"omim":[{"mim_id":"606083","title":"POLYBROMO 1; PBRM1","url":"https://www.omim.org/entry/606083"},{"mim_id":"605549","title":"CONE-ROD DYSTROPHY 8; CORD8","url":"https://www.omim.org/entry/605549"},{"mim_id":"605092","title":"PHOSPHOLIPASE A AND ACYLTRANSFERASE 4; PLAAT4","url":"https://www.omim.org/entry/605092"},{"mim_id":"605090","title":"RETINOIC ACID RECEPTOR RESPONDER 1; RARRES1","url":"https://www.omim.org/entry/605090"},{"mim_id":"604416","title":"PYOGENIC STERILE ARTHRITIS, PYODERMA GANGRENOSUM, AND ACNE; PAPA","url":"https://www.omim.org/entry/604416"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"cervix","ntpm":567.4},{"tissue":"esophagus","ntpm":1174.0},{"tissue":"vagina","ntpm":589.7}],"url":"https://www.proteinatlas.org/search/CRABP2"},"hgnc":{"alias_symbol":["CRABP-II"],"prev_symbol":[]},"alphafold":{"accession":"P29373","domains":[{"cath_id":"2.40.128.20","chopping":"5-136","consensus_level":"high","plddt":96.9033,"start":5,"end":136}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P29373","model_url":"https://alphafold.ebi.ac.uk/files/AF-P29373-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P29373-F1-predicted_aligned_error_v6.png","plddt_mean":96.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CRABP2","jax_strain_url":"https://www.jax.org/strain/search?query=CRABP2"},"sequence":{"accession":"P29373","fasta_url":"https://rest.uniprot.org/uniprotkb/P29373.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P29373/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P29373"}},"corpus_meta":[{"pmid":"30696915","id":"PMC_30696915","title":"Crabp2 Promotes Metastasis of Lung Cancer Cells via HuR and Integrin β1/FAK/ERK Signaling.","date":"2019","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/30696915","citation_count":69,"is_preprint":false},{"pmid":"20019841","id":"PMC_20019841","title":"Epigenetic silencing of CRABP2 and MX1 in head and neck tumors.","date":"2009","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/20019841","citation_count":68,"is_preprint":false},{"pmid":"31419991","id":"PMC_31419991","title":"CRABP2 regulates invasion and metastasis of breast cancer through hippo pathway dependent on ER status.","date":"2019","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/31419991","citation_count":66,"is_preprint":false},{"pmid":"30894514","id":"PMC_30894514","title":"Resveratrol inhibits decidualization by accelerating downregulation of the CRABP2-RAR pathway in differentiating human endometrial stromal cells.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30894514","citation_count":52,"is_preprint":false},{"pmid":"19173746","id":"PMC_19173746","title":"The retinoic acid binding protein CRABP2 is increased in murine models of degenerative joint disease.","date":"2009","source":"Arthritis research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/19173746","citation_count":47,"is_preprint":false},{"pmid":"16237707","id":"PMC_16237707","title":"Analysis of ALDH1A2, CYP26A1, CYP26B1, CRABP1, and CRABP2 in human neural tube defects suggests a possible association with alleles in ALDH1A2.","date":"2005","source":"Birth defects research. Part A, Clinical and molecular teratology","url":"https://pubmed.ncbi.nlm.nih.gov/16237707","citation_count":46,"is_preprint":false},{"pmid":"36195596","id":"PMC_36195596","title":"Upregulation of CRABP2 by TET1-mediated DNA hydroxymethylation attenuates mitochondrial apoptosis and promotes oxaliplatin resistance in gastric cancer.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36195596","citation_count":36,"is_preprint":false},{"pmid":"36240291","id":"PMC_36240291","title":"CRABP2 Is Associated With Thyroid Cancer Recurrence and Promotes Invasion via the Integrin/FAK/AKT Pathway.","date":"2022","source":"Endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/36240291","citation_count":31,"is_preprint":false},{"pmid":"31736873","id":"PMC_31736873","title":"Resveratrol Reverses Retinoic Acid Resistance of Anaplastic Thyroid Cancer Cells via Demethylating CRABP2 Gene.","date":"2019","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/31736873","citation_count":30,"is_preprint":false},{"pmid":"25034531","id":"PMC_25034531","title":"Expression and clinical significance of CRABP1 and CRABP2 in non-small cell lung cancer.","date":"2014","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25034531","citation_count":28,"is_preprint":false},{"pmid":"32685464","id":"PMC_32685464","title":"Downregulation of CRABP2 Inhibit the Tumorigenesis of Hepatocellular Carcinoma In Vivo and In Vitro.","date":"2020","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/32685464","citation_count":27,"is_preprint":false},{"pmid":"23833249","id":"PMC_23833249","title":"RDH10, RALDH2, and CRABP2 are required components of PPARγ-directed ATRA synthesis and signaling in human dendritic cells.","date":"2013","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/23833249","citation_count":24,"is_preprint":false},{"pmid":"23383201","id":"PMC_23383201","title":"CRABP2 promotes myoblast differentiation and is modulated by the transcription factors MyoD and Sp1 in C2C12 cells.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23383201","citation_count":23,"is_preprint":false},{"pmid":"22275178","id":"PMC_22275178","title":"Epigenetically mediated downregulation of the differentiation-promoting chaperon protein CRABP2 in astrocytic gliomas.","date":"2012","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/22275178","citation_count":20,"is_preprint":false},{"pmid":"38195606","id":"PMC_38195606","title":"CRABP2 affects chemotherapy resistance of ovarian cancer by regulating the expression of HIF1α.","date":"2024","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/38195606","citation_count":19,"is_preprint":false},{"pmid":"35442568","id":"PMC_35442568","title":"CRABP2 accelerates epithelial mesenchymal transition in serous ovarian cancer cells by promoting TRIM16 methylation via upregulating EZH2 expression.","date":"2022","source":"Environmental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/35442568","citation_count":19,"is_preprint":false},{"pmid":"35578123","id":"PMC_35578123","title":"Exosome-related protein CRABP2 is upregulated in ovarian carcinoma and enhances cell proliferation.","date":"2022","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35578123","citation_count":18,"is_preprint":false},{"pmid":"31566355","id":"PMC_31566355","title":"Retinoic Acid Binding Leads to CRABP2 Rigidification and Dimerization.","date":"2019","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31566355","citation_count":17,"is_preprint":false},{"pmid":"35396749","id":"PMC_35396749","title":"Circular RNA hsa_circ_0011298 enhances Taxol resistance of non-small cell lung cancer by regulating miR-486-3p/CRABP2 axis.","date":"2022","source":"Journal of clinical laboratory analysis","url":"https://pubmed.ncbi.nlm.nih.gov/35396749","citation_count":16,"is_preprint":false},{"pmid":"29378601","id":"PMC_29378601","title":"Tissue expression of retinoic acid receptor alpha and CRABP2 in metastatic nephroblastomas.","date":"2018","source":"Diagnostic pathology","url":"https://pubmed.ncbi.nlm.nih.gov/29378601","citation_count":16,"is_preprint":false},{"pmid":"29930489","id":"PMC_29930489","title":"Plasma CRABP2 as a Novel Biomarker in Patients with Non-Small Cell Lung Cancer.","date":"2018","source":"Journal of Korean medical science","url":"https://pubmed.ncbi.nlm.nih.gov/29930489","citation_count":16,"is_preprint":false},{"pmid":"29731607","id":"PMC_29731607","title":"4-Amino-2-trifluoromethyl-phenyl retinate inhibits proliferation, invasion, and migration of breast cancer cells by independently regulating CRABP2 and FABP5.","date":"2018","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/29731607","citation_count":14,"is_preprint":false},{"pmid":"38186580","id":"PMC_38186580","title":"CRABP2 regulates infiltration of cancer-associated fibroblasts and immune response in melanoma.","date":"2023","source":"Oncology research","url":"https://pubmed.ncbi.nlm.nih.gov/38186580","citation_count":12,"is_preprint":false},{"pmid":"36163055","id":"PMC_36163055","title":"CRABP2 - A novel biomarker for high-risk endometrial cancer.","date":"2022","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36163055","citation_count":12,"is_preprint":false},{"pmid":"37715025","id":"PMC_37715025","title":"The heterogeneity of tumour immune microenvironment revealing the CRABP2/CD69 signature discriminates distinct clinical outcomes in breast cancer.","date":"2023","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37715025","citation_count":12,"is_preprint":false},{"pmid":"17484622","id":"PMC_17484622","title":"Association of a polymorphism in the promoter of the cellular retinoic acid-binding protein II gene (CRABP2) with increased circulating low-density lipoprotein cholesterol.","date":"2007","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17484622","citation_count":10,"is_preprint":false},{"pmid":"38807101","id":"PMC_38807101","title":"FOXD2-AS1 promotes malignant cell behavior in oral squamous cell carcinoma via the miR-378 g/CRABP2 axis.","date":"2024","source":"BMC oral health","url":"https://pubmed.ncbi.nlm.nih.gov/38807101","citation_count":9,"is_preprint":false},{"pmid":"35966249","id":"PMC_35966249","title":"MiR-579 Inhibits Lung Adenocarcinoma Cell Proliferation and Metastasis via Binding to CRABP2.","date":"2022","source":"Computational and mathematical methods in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35966249","citation_count":8,"is_preprint":false},{"pmid":"39038078","id":"PMC_39038078","title":"CRABP2 promotes cell migration and invasion by activating PI3K/AKT and MAPK signalling pathways via upregulating LAMB3 in prostate cancer.","date":"2024","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39038078","citation_count":8,"is_preprint":false},{"pmid":"34632074","id":"PMC_34632074","title":"Expression and function analysis of CRABP2 and FABP5, and their ratio in esophageal squamous cell carcinoma.","date":"2021","source":"Open medicine (Warsaw, Poland)","url":"https://pubmed.ncbi.nlm.nih.gov/34632074","citation_count":8,"is_preprint":false},{"pmid":"23458901","id":"PMC_23458901","title":"Duplicated crabp1 and crabp2 genes in medaka (Oryzias latipes): gene structure, phylogenetic relationship and tissue-specific distribution of transcripts.","date":"2013","source":"Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/23458901","citation_count":7,"is_preprint":false},{"pmid":"37370543","id":"PMC_37370543","title":"CRABP2 Promotes the Proliferation of Dermal Papilla Cells via the Wnt/β-Catenin Pathway.","date":"2023","source":"Animals : an open access journal from MDPI","url":"https://pubmed.ncbi.nlm.nih.gov/37370543","citation_count":6,"is_preprint":false},{"pmid":"33832420","id":"PMC_33832420","title":"CRABP1 and CRABP2 Protein Levels Correlate with Each Other but Do Not Correlate with Sensitivity of Breast Cancer Cells to Retinoic Acid.","date":"2021","source":"Biochemistry. Biokhimiia","url":"https://pubmed.ncbi.nlm.nih.gov/33832420","citation_count":6,"is_preprint":false},{"pmid":"34932899","id":"PMC_34932899","title":"CRABP2 involvement in a mechanism of Golgi stress and tumor dry matter in non-small cell lung cancer cells via ER dependent Hippo pathway.","date":"2021","source":"Acta biochimica Polonica","url":"https://pubmed.ncbi.nlm.nih.gov/34932899","citation_count":6,"is_preprint":false},{"pmid":"33879199","id":"PMC_33879199","title":"Overexpression of CRABP2 inhibits dexamethasone-induced apoptosis in human osteoblast cells.","date":"2021","source":"Journal of orthopaedic surgery and research","url":"https://pubmed.ncbi.nlm.nih.gov/33879199","citation_count":5,"is_preprint":false},{"pmid":"36568517","id":"PMC_36568517","title":"Dezocine inhibits cell proliferation, migration, and invasion by targeting CRABP2 in ovarian cancer.","date":"2022","source":"Open medicine (Warsaw, Poland)","url":"https://pubmed.ncbi.nlm.nih.gov/36568517","citation_count":5,"is_preprint":false},{"pmid":"38001389","id":"PMC_38001389","title":"Cellular Retinoic Acid Binding Protein 2 (CRABP2), Up-regulated by HPV E6/E7, Leads to Aberrant Activation of the Integrin β1/FAK/ERK Signaling Pathway and Aggravates the Malignant Phenotypes of Cervical Cancer.","date":"2023","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38001389","citation_count":5,"is_preprint":false},{"pmid":"39768218","id":"PMC_39768218","title":"GRPR Drives Metastasis via CRABP2 and FNDC4 Pathways in Lung Adenocarcinoma.","date":"2024","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/39768218","citation_count":4,"is_preprint":false},{"pmid":"30031031","id":"PMC_30031031","title":"DNA methylation status of CRABP2 promoter down-regulates its expression.","date":"2018","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/30031031","citation_count":4,"is_preprint":false},{"pmid":"29267673","id":"PMC_29267673","title":"Effect of CRABP2 on the proliferation and odontoblastic differentiation of hDPSCs.","date":"2017","source":"Brazilian oral research","url":"https://pubmed.ncbi.nlm.nih.gov/29267673","citation_count":4,"is_preprint":false},{"pmid":"38493911","id":"PMC_38493911","title":"CRABP2 reduces the sensitivity of Olaparib in ovarian cancer by downregulating Caspase-8 and decreasing the production of reactive oxygen species.","date":"2024","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/38493911","citation_count":4,"is_preprint":false},{"pmid":"39450531","id":"PMC_39450531","title":"Melittin promotes the proliferation of Schwann cells in hyperglycemic environment by up‑regulating the Crabp2/Wnt/β‑catenin signaling pathway.","date":"2024","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/39450531","citation_count":4,"is_preprint":false},{"pmid":"40305785","id":"PMC_40305785","title":"Dual Role of CRABP2 in Colorectal Cancer: Oncogenesis via Nuclear RB1 and Cytoplasmic AFG3L2/SLC25A39 Axis, While Limiting Liver Metastasis through Cytoplasmic AFG3L2/PINK1/Parkin-Mediated Mitophagy.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/40305785","citation_count":3,"is_preprint":false},{"pmid":"32780252","id":"PMC_32780252","title":"Analysis of CRABP2 and FABP5 genes in primary and recurrent pterygium tissues.","date":"2020","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/32780252","citation_count":3,"is_preprint":false},{"pmid":"30570383","id":"PMC_30570383","title":"Exploring genotype-phenotype relationships of the CRABP2 gene on growth traits in beef cattle.","date":"2018","source":"Animal biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/30570383","citation_count":3,"is_preprint":false},{"pmid":"38462454","id":"PMC_38462454","title":"Opposite Effects of CRABP1 and CRABP2 Homologs on Proliferation of Breast Cancer Cells and Their Sensitivity to Retinoic Acid.","date":"2023","source":"Biochemistry. Biokhimiia","url":"https://pubmed.ncbi.nlm.nih.gov/38462454","citation_count":2,"is_preprint":false},{"pmid":"34179706","id":"PMC_34179706","title":"DCX and CRABP2 are candidate genes for differential diagnosis between pre-chemotherapy embryonic and alveolar rhabdomyosarcoma in pediatric patients.","date":"2021","source":"Pediatric investigation","url":"https://pubmed.ncbi.nlm.nih.gov/34179706","citation_count":2,"is_preprint":false},{"pmid":"40505846","id":"PMC_40505846","title":"CRABP2 promotes peritoneal metastasis in CRC through TGF-β/Smad-mediated EMT signaling and invadopodia formation.","date":"2025","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/40505846","citation_count":1,"is_preprint":false},{"pmid":"40499532","id":"PMC_40499532","title":"SPP1+ Venous Endothelial Cells and CRABP2+ Tumor Cells Contribute to Favorable Body and Tail Pancreatic Ductal Adenocarcinoma Tumor Microenvironment.","date":"2025","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/40499532","citation_count":1,"is_preprint":false},{"pmid":"40371351","id":"PMC_40371351","title":"Canagliflozin alleviates progestin resistance by suppressing RARβ/CRABP2 signaling in THRB knockout endometrial cancer cells.","date":"2025","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40371351","citation_count":1,"is_preprint":false},{"pmid":"39419021","id":"PMC_39419021","title":"Structural requirements for the specific binding of CRABP2 to cyclin D3.","date":"2024","source":"Structure (London, England : 1993)","url":"https://pubmed.ncbi.nlm.nih.gov/39419021","citation_count":1,"is_preprint":false},{"pmid":"38827116","id":"PMC_38827116","title":"Identification of cellular retinoic acid binding protein 2 (CRABP2) as downstream target of nuclear factor I/X (NFIX): implications for skeletal dysplasia syndromes.","date":"2024","source":"JBMR plus","url":"https://pubmed.ncbi.nlm.nih.gov/38827116","citation_count":1,"is_preprint":false},{"pmid":"40657374","id":"PMC_40657374","title":"CRABP2 promotes metastasis and lipid droplet accumulation in non-small cell lung cancer by downregulating PLAAT4.","date":"2025","source":"Journal of Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/40657374","citation_count":0,"is_preprint":false},{"pmid":"41145842","id":"PMC_41145842","title":"ZEB1 and ALKBH5 coregulate CRABP2 and FABP5 and jointly determine the sensitivity of anaplastic thyroid cancers to gemcitabine and retinoic acid.","date":"2025","source":"NPJ precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41145842","citation_count":0,"is_preprint":false},{"pmid":"38607221","id":"PMC_38607221","title":"Mechanistic Study of CRABP2: Accelerating Lung Cancer Migration and Metastasis through Regulation of the ROS/Src Signaling Pathway.","date":"2025","source":"Alternative therapies in health and medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38607221","citation_count":0,"is_preprint":false},{"pmid":"37538489","id":"PMC_37538489","title":"Retracted: MiR-579 Inhibits Lung Adenocarcinoma Cell Proliferation and Metastasis via Binding to CRABP2.","date":"2023","source":"Computational and mathematical methods in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/37538489","citation_count":0,"is_preprint":false},{"pmid":"41975397","id":"PMC_41975397","title":"CRABP2 upregulation in perichondral stem cells is associated with microtia.","date":"2026","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/41975397","citation_count":0,"is_preprint":false},{"pmid":"41629950","id":"PMC_41629950","title":"MSCs-derived CRABP2 regulates Treg/CXCL1 to ameliorate alcohol-induced liver injury.","date":"2026","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/41629950","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":32438,"output_tokens":4860,"usd":0.085107,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":13212,"output_tokens":3736,"usd":0.07973,"stage2_stop_reason":"end_turn"},"total_usd":0.164837,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2019,\n      \"finding\": \"CRABP2 was co-immunoprecipitated with HuR in lung cancer cells, and overexpression of CRABP2 increased HuR protein levels, which in turn promoted integrin β1/FAK/ERK signaling to drive migration, invasion, and anoikis resistance.\",\n      \"method\": \"Co-immunoprecipitation, overexpression, knockdown with pathway inhibitors\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP and pathway rescue experiments, single lab, two orthogonal approaches\",\n      \"pmids\": [\"30696915\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In ER+ breast cancer cells, CRABP2 interacts with LATS1 and suppresses its ubiquitination-mediated degradation, thereby activating the Hippo pathway and inhibiting invasion/metastasis. Conversely, in ER− breast cancer cells, CRABP2 interaction with LATS1 promotes LATS1 ubiquitination, inactivating Hippo and promoting metastasis.\",\n      \"method\": \"Co-immunoprecipitation, Western blotting, shRNA knockdown, overexpression, tail-vein injection in vivo metastasis model\",\n      \"journal\": \"Journal of experimental & clinical cancer research : CR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus in vivo rescue, single lab, two orthogonal methods\",\n      \"pmids\": [\"31419991\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CRABP2 physically delivers all-trans retinoic acid (atRA) to retinoic acid receptors (RARs); NMR spectroscopy demonstrated that atRA binding suppresses widespread intermediate- and fast-time scale dynamics in CRABP2, leading to rigidification that stabilizes a homodimerization interface (helix α2, βC-βD loop, strands βI-βA, βH-βI loop) and reorganizes the nuclear localization signal and RAR-binding motif.\",\n      \"method\": \"Nuclear magnetic resonance (NMR) spectroscopy with functional validation of dynamic changes\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structural/dynamics study with detailed residue-level mapping of ligand-induced conformational changes, single lab but multiple NMR approaches\",\n      \"pmids\": [\"31566355\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Knockdown of CRABP2 or RAR in human endometrial stromal cells (HESCs) recapitulated the anti-deciduogenic effects of resveratrol, establishing that the CRABP2–RAR signaling axis is required for decidualization (induction of PRL, IGFBP1, and decidual senescence markers).\",\n      \"method\": \"siRNA knockdown, primary HESC culture, qPCR for decidual markers\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with specific cellular phenotype, single lab, two targets knocked down independently with convergent results\",\n      \"pmids\": [\"30894514\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CRABP2, RDH10, and RALDH2 form a linear PPARγ-regulated pathway required for ATRA production and signaling in human monocyte-derived dendritic cells; all three proteins were shown to be required for PPARγ-induced ATRA production.\",\n      \"method\": \"Functional knockdown, co-localization, PPARγ activation assays in human and murine DCs\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pathway epistasis via genetic knockdown of each component, single lab, multiple cell types tested\",\n      \"pmids\": [\"23833249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CRABP2 promotes myoblast differentiation in C2C12 cells by regulating the cell cycle; its core promoter (−459 to −4 bp) contains MyoD and Sp1 binding sites, and EMSA plus site-directed mutagenesis confirmed that MyoD and Sp1 directly regulate CRABP2 transcription.\",\n      \"method\": \"Overexpression, site-directed mutagenesis, EMSA, promoter deletion analysis, C2C12 differentiation assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution (EMSA), mutagenesis, and functional differentiation assay in single study with multiple orthogonal methods\",\n      \"pmids\": [\"23383201\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CRABP2 expedites the binding of BAX and PARKIN (shown by Co-IP and GST pulldown), facilitating ubiquitination-mediated degradation of BAX, thereby attenuating mitochondrial apoptosis and promoting oxaliplatin resistance in gastric cancer cells.\",\n      \"method\": \"Co-immunoprecipitation, GST pulldown, ubiquitination assay, shRNA knockdown, CDX and PDX in vivo models\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — GST pulldown (Tier 1) plus Co-IP, ubiquitination assay, and in vivo validation; single lab, multiple orthogonal methods\",\n      \"pmids\": [\"36195596\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CRABP2 upregulates EZH2 expression in ovarian cancer cells (confirmed by Co-IP), and EZH2 then binds DNMT1 to methylate the TRIM16 promoter, silencing TRIM16 and promoting EMT and invasion.\",\n      \"method\": \"Co-immunoprecipitation, ChIP assay, bisulfite sequencing, siRNA knockdown, overexpression, in vivo xenograft\",\n      \"journal\": \"Environmental toxicology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus ChIP plus functional epistasis rescue, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"35442568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CRABP2 is a cyclin D3-specific binding protein; purified protein binding assays and structural analysis revealed that the CRABP2 cyclin D3-binding site overlaps with its nuclear localization sequence within the helix-loop-helix motif. Mutations blocking cyclin D3 binding also blocked retinoic acid binding and induced an alternative lid conformation occluding the binding pocket. AlphaFold modelling supported a ternary CDK4/6–cyclin D3–CRABP2 complex.\",\n      \"method\": \"In vitro binding assays with purified proteins, mutagenesis, X-ray crystallography (structural analysis), AlphaFold modelling\",\n      \"journal\": \"Structure (London, England : 1993)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution with purified proteins, mutagenesis, and structural data in single study with multiple orthogonal methods\",\n      \"pmids\": [\"39419021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Nuclear CRABP2 promotes colorectal cancer tumor growth by interacting with and downregulating the tumor suppressor RB1, while cytoplasmic CRABP2 interacts with AFG3L2 to promote PINK1/Parkin-mediated mitophagy that suppresses liver metastasis. A separate cytoplasmic AFG3L2–SLC25A39 axis was identified whereby CRABP2 increases mitochondrial glutathione stability to promote proliferation independently of nuclear RB1.\",\n      \"method\": \"Conditional knockout mouse model (Crabp2ΔIEC), subcutaneous xenograft, Co-IP (CRABP2–RB1, CRABP2–AFG3L2), in vitro and in vivo functional assays\",\n      \"journal\": \"Advanced science (Weinheim, Baden-Wurttemberg, Germany)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO mouse model plus multiple Co-IPs and in vivo validation, single lab but multiple orthogonal methods establishing distinct nuclear vs cytoplasmic mechanisms\",\n      \"pmids\": [\"40305785\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"CRABP2 expression in thyroid cancer cells promotes invasion via the integrin/focal adhesion kinase (FAK)/AKT signaling pathway, independent of canonical retinoic acid signaling; knockdown reduced retinoic acid sensitivity.\",\n      \"method\": \"shRNA knockdown, overexpression, invasion assays, pathway inhibition experiments\",\n      \"journal\": \"Endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — KD/OE with defined cellular phenotype and pathway inhibitor rescue, single lab\",\n      \"pmids\": [\"36240291\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"HPV16 E6/E7 upregulates CRABP2 expression in cervical cancer cells; CRABP2 in turn activates integrin β1/FAK/ERK signaling via HuR to promote proliferation, migration, and invasion. Inhibition of ITGB1, FAK, or ERK reversed the CRABP2-driven phenotypes.\",\n      \"method\": \"siRNA knockdown, overexpression, Co-IP (CRABP2–HuR inferred from prior work), pathway inhibitors, HPV E6/E7 knockdown rescue\",\n      \"journal\": \"Biochemical genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis via pathway inhibitors plus HPV E6/E7 genetic manipulation, single lab\",\n      \"pmids\": [\"38001389\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CRABP2 promotes migration and invasion in prostate cancer cells by upregulating LAMB3 mRNA and protein, activating downstream PI3K/AKT and MAPK signaling pathways, as confirmed by RNA-seq and Western blotting.\",\n      \"method\": \"RNA-seq, overexpression, Western blotting, in vivo xenograft\",\n      \"journal\": \"Journal of biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — RNA-seq plus Western blot pathway validation plus in vivo, single lab\",\n      \"pmids\": [\"39038078\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CRABP2 reduces ovarian cancer sensitivity to Olaparib by inhibiting Caspase-8 activity and decreasing ROS production; knockdown of CRABP2 activated Caspase-8 and increased ROS, enhancing Olaparib sensitivity in vitro and in xenograft models, and Caspase-8 knockdown reversed this effect.\",\n      \"method\": \"shRNA knockdown, flow cytometry (ROS, apoptosis), colony formation, Western blotting, 4D proteomics, xenograft\",\n      \"journal\": \"Chemico-biological interactions\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic epistasis (Caspase-8 rescue) plus in vivo validation, single lab, multiple methods\",\n      \"pmids\": [\"38493911\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"NFIX directly regulates CRABP2 promoter activity, as demonstrated by in vitro luciferase reporter assays; CRABP2 was identified as a downstream transcriptional target of NFIX in mouse embryonic fibroblasts and confirmed in Marshall-Smith syndrome patient fibroblasts.\",\n      \"method\": \"Luciferase reporter assay, RNA sequencing, proteomics, qRT-PCR, Western blot in MEFs and patient fibroblasts\",\n      \"journal\": \"JBMR plus\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — luciferase reporter (Tier 1) but single lab, confirmed in patient cells as additional validation\",\n      \"pmids\": [\"38827116\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CRABP2 knockdown in breast cancer cells suppressed CRABP1 protein levels, demonstrating a CRABP2-dependent regulation of CRABP1 expression as a novel mechanism within the intracellular retinoic acid signaling system.\",\n      \"method\": \"shRNA knockdown of CRABP2, Western blotting for CRABP1 across multiple breast cancer cell lines\",\n      \"journal\": \"Biochemistry. Biokhimiia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — single method (Western blot) but replicated across multiple cell lines of different origin, single lab\",\n      \"pmids\": [\"33832420\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TRβ negatively regulates RARβ expression by binding to its promoter, and RARβ positively regulates CRABP2 expression; demonstrated by EMSA and dual luciferase reporter assays in endometrial cancer cells.\",\n      \"method\": \"Electrophoretic mobility shift assay (EMSA), dual luciferase reporter assay, Western blotting, xenograft model\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Weak — EMSA and reporter assay are Tier 1 methods, but single lab and single study\",\n      \"pmids\": [\"40371351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"CRABP2 binds PLAAT4 protein and decreases its stability; PLAAT4 inhibition reversed the suppression of malignant phenotypes (migration, invasion, lipid droplet accumulation) caused by CRABP2 knockdown in NSCLC cells.\",\n      \"method\": \"Protein binding assay, shRNA knockdown, overexpression, xenograft, lipid droplet staining\",\n      \"journal\": \"Journal of Cancer\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, binding assay not fully described in abstract, rescue epistasis without full mechanistic detail\",\n      \"pmids\": [\"40657374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"MSC-secreted CRABP2 increases the proportion of regulatory T cells (Tregs), which suppress hepatic CXCL1/neutrophil axis inflammation in alcohol-induced liver injury; Treg depletion negated the protective effect of MSC-derived CRABP2.\",\n      \"method\": \"MSC infusion in mouse model, Foxp3-DTR/EGFP transgenic Treg-depletion, anti-CXCL1 treatment, flow cytometry\",\n      \"journal\": \"Cell communication and signaling : CCS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic Treg depletion epistasis plus in vivo rescue experiment, single lab\",\n      \"pmids\": [\"41629950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CRABP2 upregulates HIF1α protein levels and increases HIF1α nuclear localization in drug-resistant ovarian cancer cells; knockdown of HIF1α blocked the CRABP2-mediated chemotherapy resistance.\",\n      \"method\": \"shRNA knockdown, Western blotting, nuclear fractionation/immunofluorescence, cell viability assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — epistasis via HIF1α knockdown rescue, single lab, two orthogonal readouts (expression and localization)\",\n      \"pmids\": [\"38195606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"In colorectal cancer, CRABP2 promotes peritoneal metastasis through TGF-β/Smad-mediated EMT signaling and invadopodia formation; bioinformatics plus experimental validation showed CRABP2 drives cell protrusive structures and EMT marker changes.\",\n      \"method\": \"shRNA knockdown, overexpression, in vivo metastasis model, enrichment analyses with experimental verification of TGF-β/Smad pathway\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pathway placement primarily from enrichment analysis with limited direct mechanistic confirmation in abstract, single lab\",\n      \"pmids\": [\"40505846\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CRABP2 is a cytoplasmic/nuclear lipid-binding protein that transports all-trans retinoic acid (atRA) to nuclear RAR receptors (a process accompanied by ligand-induced protein rigidification and homodimerization); it also functions as a cyclin D3-specific binding partner, regulates HuR-mediated integrin β1/FAK/ERK signaling to drive cancer cell invasion, modulates LATS1 stability to control Hippo pathway activity in an ER-status-dependent manner, facilitates BAX ubiquitination via PARKIN to attenuate mitochondrial apoptosis, and in its nuclear vs. cytoplasmic forms plays opposing roles in colorectal cancer—nuclear CRABP2 downregulates RB1 to promote tumor growth while cytoplasmic CRABP2 engages AFG3L2/PINK1/Parkin-mediated mitophagy to suppress metastasis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CRABP2 is an intracellular all-trans retinoic acid (atRA) binding protein that physically delivers atRA to nuclear retinoic acid receptors (RARs), and ligand binding suppresses its conformational dynamics, rigidifying the protein to stabilize a homodimerization interface and reorganize the nuclear localization signal and RAR-binding motif [#2]. This CRABP2-RAR axis is required for tissue-specific differentiation programs including endometrial stromal cell decidualization [#3] and PPARγ-driven atRA production in dendritic cells, where CRABP2 acts within a linear RDH10/RALDH2 pathway [#4]. Beyond retinoid transport, structural and reconstitution work establishes CRABP2 as a cyclin D3-specific binding partner whose cyclin D3-binding site overlaps its nuclear localization sequence within the helix-loop-helix motif, supporting a ternary CDK4/6-cyclin D3-CRABP2 complex; mutations that block cyclin D3 binding also abolish retinoic acid binding [#8]. CRABP2 functions extensively as a protein-stability and signaling regulator in cancer: it binds HuR to drive integrin β1/FAK/ERK signaling and invasion [#0, #11], modulates LATS1 ubiquitination to tune Hippo pathway output in an estrogen-receptor-status-dependent manner [#1], and promotes BAX ubiquitination via PARKIN to attenuate mitochondrial apoptosis and confer chemoresistance [#6]. In colorectal cancer it exerts opposing compartment-specific roles, with nuclear CRABP2 downregulating the tumor suppressor RB1 to promote growth while cytoplasmic CRABP2 engages AFG3L2 to drive PINK1/Parkin mitophagy that suppresses metastasis [#9]. CRABP2 transcription is directly controlled by MyoD and Sp1 during myoblast differentiation [#5] and by NFIX [#14].\",\n  \"teleology\": [\n    {\n      \"year\": 2013,\n      \"claim\": \"Establishing how CRABP2 is itself controlled and what cellular program it serves, transcriptional and pathway-level studies placed it within differentiation circuits.\",\n      \"evidence\": \"EMSA, promoter deletion and mutagenesis in C2C12 myoblasts; functional knockdown and co-localization in human/murine dendritic cells\",\n      \"pmids\": [\"23383201\", \"23833249\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the same transcriptional inputs operate in non-muscle tissues was not addressed\", \"The DC pathway epistasis did not resolve direct biochemical handoffs between RDH10, RALDH2 and CRABP2\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Residue-level structural dynamics answered how atRA binding converts CRABP2 into a delivery-competent state, linking ligand occupancy to dimerization and nuclear targeting.\",\n      \"evidence\": \"NMR spectroscopy with functional validation of ligand-induced rigidification\",\n      \"pmids\": [\"31566355\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The functional consequence of homodimerization for RAR delivery in cells was not measured\", \"No structure of the CRABP2-RAR complex itself\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Co-IP and in vivo studies revealed that CRABP2 acts beyond retinoid transport as a protein-interaction hub controlling HuR-driven invasion signaling and context-dependent LATS1/Hippo regulation, and that the CRABP2-RAR axis is required for decidualization.\",\n      \"evidence\": \"Reciprocal Co-IP plus pathway inhibitor rescue in lung cancer; Co-IP with tail-vein metastasis model in ER+/ER- breast cancer; siRNA in primary endometrial stromal cells\",\n      \"pmids\": [\"30696915\", \"31419991\", \"30894514\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which ER status reverses the LATS1 ubiquitination outcome is unresolved\", \"How CRABP2 stabilizes HuR protein is not defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Biochemical and in vivo work defined CRABP2 as a ubiquitination scaffold that promotes BAX degradation via PARKIN, mechanistically connecting it to apoptosis evasion and drug resistance.\",\n      \"evidence\": \"GST pulldown, Co-IP, ubiquitination assay, shRNA, CDX/PDX models in gastric cancer\",\n      \"pmids\": [\"36195596\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CRABP2 directly bridges BAX-PARKIN or acts allosterically is unclear\", \"No structural model of the CRABP2-BAX-PARKIN assembly\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Additional cancer studies extended CRABP2's regulatory reach to epigenetic silencing (EZH2/DNMT1/TRIM16) and FAK/AKT-driven invasion independent of canonical retinoic acid signaling.\",\n      \"evidence\": \"Co-IP, ChIP, bisulfite sequencing in ovarian cancer; shRNA and pathway inhibition in thyroid cancer\",\n      \"pmids\": [\"35442568\", \"36240291\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct biochemical link between cytoplasmic CRABP2 and nuclear EZH2 upregulation not established\", \"FAK/AKT activation mechanism downstream of CRABP2 not biochemically defined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Structural reconstitution resolved a non-retinoid function of CRABP2 as a cyclin D3 partner, showing the binding sites for cyclin D3 and retinoic acid are mutually exclusive and embedded in the NLS.\",\n      \"evidence\": \"Purified protein binding assays, mutagenesis, X-ray crystallography, AlphaFold modelling of a CDK4/6-cyclin D3-CRABP2 complex\",\n      \"pmids\": [\"39419021\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular consequence of the ternary CDK4/6-cyclin D3-CRABP2 complex on cell cycle not demonstrated\", \"Whether retinoic acid competes off cyclin D3 in cells is untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"A cluster of studies mapped CRABP2 into chemoresistance and signaling outputs (HIF1α, Caspase-8/ROS, LAMB3-PI3K/AKT) and into a transcriptional network with NFIX and TRβ/RARβ.\",\n      \"evidence\": \"shRNA epistasis and xenografts in ovarian cancer; RNA-seq in prostate cancer; luciferase reporters in MEFs/patient fibroblasts and endometrial cancer cells\",\n      \"pmids\": [\"38195606\", \"38493911\", \"39038078\", \"38827116\", \"40371351\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether these downstream effectors are direct or indirect targets of CRABP2 is largely unresolved\", \"Tissue specificity of the transcriptional regulators is not generalized\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A conditional knockout mouse defined opposing subcellular roles of CRABP2 in colorectal cancer, with nuclear CRABP2 suppressing RB1 to drive growth and cytoplasmic CRABP2 engaging AFG3L2-mediated mitophagy and mitochondrial glutathione control.\",\n      \"evidence\": \"Crabp2 intestinal-epithelial conditional knockout, xenografts, multiple Co-IPs (RB1, AFG3L2)\",\n      \"pmids\": [\"40305785\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signal that partitions CRABP2 between nucleus and cytoplasm is not identified\", \"How CRABP2 downregulates RB1 mechanistically is undefined\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"An immunological role emerged for secreted CRABP2 in dampening hepatic inflammation via regulatory T-cell expansion.\",\n      \"evidence\": \"MSC infusion with Foxp3-DTR Treg depletion and anti-CXCL1 in a mouse alcohol liver injury model\",\n      \"pmids\": [\"41629950\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor or mechanism by which extracellular CRABP2 expands Tregs is unknown\", \"Whether endogenous CRABP2 secretion is physiologically relevant is untested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how a single retinoic acid carrier is dynamically partitioned among its many reported roles—retinoid delivery, cyclin D3 binding, ubiquitination scaffolding, and mitophagy—and what governs its nuclear vs cytoplasmic vs secreted distribution.\",\n      \"evidence\": \"No single study integrates the competing binding modes or compartmental switches\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unifying model for partner selection\", \"No determinant identified for subcellular targeting\", \"Physiological versus oncogenic balance of functions unclear\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0140104\", \"supporting_discovery_ids\": [2]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 6, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [9]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [2, 9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 11]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [3, 4, 5]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [6, 13]}\n    ],\n    \"complexes\": [\"CDK4/6-cyclin D3-CRABP2\"],\n    \"partners\": [\"ELAVL1\", \"LATS1\", \"CCND3\", \"BAX\", \"PARK2\", \"RB1\", \"AFG3L2\", \"PLAAT4\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}